Noticias de ARDX_US
Noticias del mercado
Últimas noticias sobre ARDX_US — 546 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
CIUDAD DE NUEVA YORK, NY / ACCESS Newswire / 19 de octubre de 2026 / Bronstein, Gewirtz & Grossman, LLC, una firma de abogados de derechos de los inversores reconocida a nivel nacional, anuncia que...
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized
ATLANTA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be
NEW YORK CITY, NY / ACCESS Newswire / October 18, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that ...
NEW YORK, NY / ACCESS Newswire / October 18, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
NEW YORK, NY / ACCESS Newswire / October 18, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
Ardelyx (ARDX) put fresh clinical data in front of investors after reporting real world results for IBSRELA at the ACG 2026 meeting, which tied tenapanor use to lower gastrointestinal related healthcare visits. The new IBSRELA data lands after a tough stretch for Ardelyx, with the share price down 39% over the past 90 days and the year to date share price return lower by 49.76%. However, the 5 year total shareholder return is still up 171.05%. Scan beyond Ardelyx and see how other under...
Ardelyx (ARDX) put fresh clinical data in front of investors after reporting real world results for IBSRELA at the ACG 2026 meeting, which tied tenapanor use to lower gastrointestinal related healthcare visits. The new IBSRELA data lands after a tough stretch for Ardelyx, with the share price down 39% over the past 90 days and the year to date share price return lower by 49.76%. However, the 5 year total shareholder return is still up 171.05%. Scan beyond Ardelyx and see how other under...
NUEVA YORK, NY / ACCESS Newswire / 17 de octubre de 2026 / Levi & Korsinsky, LLP anuncia que se ha presentado una demanda colectiva de valores en nombre de los inversores...
NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
Analistas de H.C. Wainwright elevó su precio objetivo para las acciones de Ardelyx de 10 dólares a 18 dólares.
NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
NUEVA YORK, NY - 16 de octubre de 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP anuncia que se ha presentado una demanda colectiva contra Ardelyx, Inc. ("Ardelyx" o la "Compañía") (NASDAQ: ARDX) en nombre de inversores que compraron o adquirieron de otro modo acciones ordinarias de Ardelyx entre el 13 de enero de 2025 y el 6 de agosto de 2026 (el "Período de la clase").
NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. (NASDAQ:ARDX) that Eric Foster, the Company's Chief Commercial Officer, is named as an individual defendant in a securities class action brought on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212)
Página 2 de 28